Stem cell therapy is being investigated as a supportive treatment for retinitis. It may help preserve retinal function, support healthy retinal cells, and complement conventional ophthalmic care.
Overview
Retinitis refers to inflammation or degeneration of the retina, the light-sensitive tissue at the back of the eye that is essential for vision. Depending on the underlying cause, retinitis may lead to blurred vision, reduced night vision, loss of peripheral vision, light sensitivity, or progressive vision impairment. Stem cell therapy is being studied as a regenerative approach that may support retinal cell health, reduce inflammation, and encourage tissue repair. Although it is not a cure for retinitis or inherited retinal disorders, it may complement conventional treatment and regular ophthalmic care in carefully selected patients.
Retinitis is a condition involving inflammation or damage to the retina, which plays a vital role in converting light into signals that the brain interprets as vision. The condition may occur due to infections, autoimmune diseases, inherited retinal disorders such as retinitis pigmentosa, or other underlying medical conditions. Symptoms often develop gradually and may include blurred vision, difficulty seeing in low light, reduced peripheral vision, floaters, or progressive vision loss.
Traditional treatment depends on the underlying cause of retinitis and may include medications, anti-inflammatory therapy, antiviral treatment, nutritional support, or vision rehabilitation. Stem cell therapy is being investigated as a regenerative approach that focuses on supporting retinal tissue health and cellular repair rather than treating the underlying disease directly. It is intended to complement—not replace—standard ophthalmic care.
Stem cell therapy cannot restore retinal cells that have already been permanently lost or cure inherited retinal diseases. Current research is focused on determining whether regenerative therapies may help preserve remaining retinal cells, reduce inflammation, and support retinal function in selected patients.
Mesenchymal stromal cells (MSCs) release growth factors, cytokines, and signaling molecules that may reduce inflammation, support healthy blood circulation, protect retinal cells, and encourage tissue repair. Researchers continue to study whether these regenerative properties may help maintain retinal health and slow disease progression.
Treatment outcomes vary depending on the underlying cause of retinitis, disease stage, retinal damage, and overall eye health. Some patients may experience stabilization of symptoms or gradual functional improvements, while others may have limited response. Continued monitoring by an ophthalmologist remains essential.
Eligibility is determined after a comprehensive ophthalmic evaluation. Eye specialists assess retinal imaging, visual acuity, visual field testing, disease progression, underlying diagnosis, and overall health before determining whether stem cell therapy may be appropriate.
Before treatment, patients undergo a detailed eye examination that may include retinal imaging (OCT), fundus photography, fluorescein angiography when indicated, visual field testing, and review of medical history, medications, and previous eye treatments.
| Area | Possible Changes |
|---|---|
| Retinal Health | May support healthier retinal tissue and cellular function. |
| Inflammation | May reduce inflammation affecting retinal tissues. |
| Visual Function | May help preserve remaining visual function in selected patients. |
| Night Vision | May support visual performance in low-light conditions. |
| Peripheral Vision | May help maintain remaining peripheral vision. |
| Retinal Protection | Supports the health of retinal nerve cells. |
| Disease Progression | May complement conventional treatment aimed at slowing retinal degeneration. |
| Quality of Life | May help maintain independence and daily visual function. |
| Factor | Medical Assessment |
|---|---|
| Age | Adults with retinitis or inherited retinal disorders may be evaluated individually. |
| Diagnosis | A confirmed diagnosis by an ophthalmologist or retinal specialist is required. |
| Disease Stage | Doctors assess retinal structure, remaining vision, and disease progression before recommending treatment. |
| Overall Health | Candidates should be medically stable and suitable for regenerative therapy. |
| Current Treatment | Existing medications, previous eye procedures, and ophthalmic history are reviewed during treatment planning. |
Expected Benefits